Drug Trial Radar · NCT04711135
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
11
Actual
Start
Aug 31, 2022
Primary completion
Mar 12, 2024
Study completion Feb 6, 2034
Sponsor
- Lead sponsor
- Advanced Accelerator ApplicationsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.
Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Pheochromocytoma
- Paraganglioma
Interventions
Lutetium [177Lu] oxodotreotide/dotatateDrug
Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absorbed Radiation Doses in Target OrganTime frame: Up to 8 days after the first Lutetium [Lu 177] dotatate dose
- Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera AdministrationTime frame: during first cycle of Lutetium [Lu 177] dotatate treatment (Cycle = 56 days)
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
University of Kentucky
Lexington, Kentucky
Cincinnati Children's Hospital
Cincinnati, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Centre Léon Berard
Lyon, France
Maria Sklodowska-Curie National Research Institute of Oncology
Gliwice, Poland
Hospital Universitari Vall d'Hebron
Barcelona, Spain
University College Hospital of London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.